| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Urolithins are gut microbiota–derived dibenzopyran-6-one metabolites formed from ellagitannins → ellagic acid. They are the bioactive, systemically relevant forms responsible for most of the anticancer, mitochondrial, and signaling effects attributed to pomegranate and berry consumption. Ellagic acid itself is largely confined to the gut lumen; urolithins are what reach circulation and tissues. Urolithin A (UA), Most studied; mitophagy, anticancer, anti-inflammatory Humans fall into urolithin metabotypes: Metabotype Description Approx. Population A Produces UA (best profile) ~40% B Produces UB ± UA ~25–30% 0 Non-producer ~30% ROS Modulation (Context-Dependent) Cancer cells: -Mild ROS ↑ or redox stress → apoptosis, growth arrest Normal cells: -ROS ↓, improved mitochondrial efficiency This duality is why urolithins are less chemo-antagonistic than classic antioxidants. Anticancer Signaling ↓ PI3K/AKT/mTOR ↓ Wnt/β-catenin ↓ NF-κB, STAT3 Cell-cycle arrest (G1/S) Unlike sulforaphane or NAC, urolithins: -Do not strongly upregulate NRF2 in cancer cells -May normalize NRF2 signaling in normal cellsDirect Urolithin A Supplements: Bypass microbiome dependency Urolithin A–type activity — Cancer vs Normal Cell Effects
|
| Source: |
| Type: |
| Process through which new blood vessels. Angiogenesis, the process of new blood vessel formation from pre-existing vessels, plays a crucial role in cancer progression and metastasis. Tumors require a blood supply to grow beyond a certain size and to spread to other parts of the body. Vascular Endothelial Growth Factor (VEGF): VEGF is one of the most important pro-angiogenic factors. It stimulates endothelial cell proliferation and migration, leading to the formation of new blood vessels. Many tumors overexpress VEGF, which correlates with poor prognosis. Hypoxia-Inducible Factor (HIF): In response to low oxygen levels (hypoxia), tumors can activate HIF, which in turn promotes the expression of VEGF and other angiogenic factors. This mechanism allows tumors to adapt to their microenvironment and sustain growth. |
| 4833- | Uro, | Unveiling the potential of Urolithin A in Cancer Therapy: Mechanistic Insights to Future Perspectives of Nanomedicine |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | IBD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:383 Target#:447 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid